SCHEMBL5536334

SCHEMBL5536334

Oc1ccc(N2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 1/20 0.66
ME1 P48163 1/20 0.66
ME3 Q16798 1/20 0.66
CA12 O43570 1/20 0.60
CA2 P00918 1/20 0.60
CA9 Q16790 1/20 0.60
KIF11 P52732 1/20 0.57
AKR1C3 P42330 1/20 0.57
DEGS1 O15121 2/20 0.52
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPT P10636 2/20 0.52
PKM P14618 1/20 0.52
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
HTT P42858 1/20 0.49
MLYCD O95822 1/20 0.49
DHFR P00374 1/20 0.49
NOTUM Q6P988 1/20 0.49
DRD4 P21917 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28650484 0.89 CA12 (0.65) ME2ME1ME3CA12CA2
SCHEMBL5534999 0.86 DRD4 (0.66) ME2ME1ME3DEGS1KDM4E
SCHEMBL27301750 0.84 ME2 (0.66) ME2ME1ME3CA12CA2
SCHEMBL17659675 0.84 ME2 (0.51) ME2ME1ME3CA12CA2
SCHEMBL13279945 0.84 ME2 (0.51) ME2ME1ME3CA12CA2
SCHEMBL13279218 0.84 ME2 (0.51) ME2ME1ME3CA12CA2
SCHEMBL5547210 0.83 ADRA1D (0.62) ME2ME1ME3CA2CA9
SCHEMBL7041242 0.82 MAPT (0.68) ME2ME1ME3CA12CA2
SCHEMBL13279325 0.82 OPRL1 (0.51) ME2ME1ME3CA12CA2
SCHEMBL10563838 0.82 MAPT (0.70) ME2ME1ME3DEGS1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ME2 561/4885ME1 206/4885ME3 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.